Active Ingredients
Active ingredients
Glycerin 0.5%
Naphazoline hydrochloride 0.03%
The following Structured Product Label (SPL) was submitted to the FDA by Cvs Pharmacy, Inc. for the product Cvs Maximum Redness Relief (NDC 51316-837). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredients, otc - purpose, indications & usage, warnings, do not use, otc - ask doctor, otc - when using, otc - stop use, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Active ingredients
Glycerin 0.5%
Naphazoline hydrochloride 0.03%
Purposes
Glycerin....Lubricant
Naphazoline HCl....Redness Reliever
Uses
• for the relief of redness of the eye due to minor eye irritations
• for the temporary relief of burning and irritation due to dryness of the eye
• for use as a protectant against further irritation or dryness of the eye
For external use only
Do not use if solution changes color or becomes cloudy
Ask a doctor before use if you have narrow angle glaucoma
When using this product
• to avoid contamination, do not touch tip of container to any surface
• replace cap after using
• overuse may produce increased redness of the eye
• pupils may become enlarged temporarily
Stop use and ask a doctor if
• you experience eye pain
• you experience changes in vision
• you experience continued redness or irritation of the eye
• the condition worsens or persists for more than 72 hours
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
Directions
instill 1 or 2 drops in the affected eye(s) up to 4 times daily.
Other information
• store at room temperature
• remove contact lenses before using
Inactive ingredients
benzalkonium chloride, boric acid, edetate disodium, purified water, sodium borate
* Please review the disclaimer below.